CHML

The CHML Treatment

A review from the Eclectic Medicine International (EMI) staff at http://www.holisticcancersolutions.com/

GLORY PHARMACEUTICALS:
"This is another breakthrough cancer therapy. It is very new, based on recent biological discoveries. We have talked to patients whose inoperable tumors were reduced 65-70% within a few weeks. According to the information below, the treatment is non-toxic, benign, and very effective.

GENERAL INFORMATION
To eliminate every malignant cell, an anticancer drug must overcome
many formidable obstacles presented by a tumor mass.

The drug must travel through the tumor’s intricate network of blood vessels
and disperse through the vessel walls into the interstitum – an area inside
the tumor that is rich in a tough connective tissue protein called collagen.
From there, the drug must enter directly into cancer cells, which typically
occupy less than 50% of the total volume of a tumor.

Unfortunately, the cancer cell has an abundance of defense mechanisms to
block the full penetration of chemotherapeutic agents.

What makes CHML different, is that its molecule is 33,000 times smaller
than normal cells, enabling it's penetration into the tumor mass. But more
importantly, this facilitates its permeation directly into the cancer cell itself.
Once it enters the cell, CHML is able to induce apoptosis (or "programmed
cancer cell death.").
Apoptosis programs cancer cells to commit suicide.
CHML has been called a biological, "cancer seeking missile". It is patented
worldwide, and currently is under evaluation in the United States for cancer
therapy.
Over 500 patients received so far CHML treatments. Many of them were late stage patients. Usually, these patients have exhausted a broad range of conventional and/or alternative cancer treatments. Those with a history of significant conventional intervention are normally the most difficult to treat. However, even in these cases, CHML has been successful.

Most importantly, CHML treatment has been accompanied by virtually none of the side effects commonly associated with cancer chemotherapy.

CHML may be administered by: IV drip, local injection, or by a sophisticated
new technology which allows area-specific, concentrated drug delivery. Using
DSA (Digital Subtraction Angiography), CHML is delivered directly to a site
of major concern by Arterial Infusion.

Used regularly in Cardiology practice, this technology is capable of delivering
concurrent imaging of the intricate blood vessel network of a tumor. DSA is
used to guide the delivery of CHML, as well as measure the immediate effects
on the tumors blood supply network.

***********************************************

Glory Pharmaceuticals
"Working to provide restored health and a new future -
for individuals dealing with a terminal diagnoses. . ."

Scientific Background
Cell death was once thought to be a passive non-specific event, but is now known to be an active biochemical process. Scientists have discovered that any cells have the ability to die by this process, called programmed cell death or apoptosis.

A number of important human diseases are caused by abnormal apoptosis control mechanisms, which can result in either a pathological increase in the number of cells (e.g. cancer) or a damaging loss of cells (e.g. degenerative diseases). Recent data has shown that cells have a discrete cell death pathway defined by a specific set of genes. These genes encode proteins that form the biochemical process that ultimately invokes cell death.

The key genes that control the cell death process are the cell death effectors of the CED-3/ICE ("caspase") family and the cell death inhibitors of the Bcl-2 family. The caspase gene family encodes a set of proteases responsible for carrying out the death process. In a living cell, these proteases are normally kept inactive by proteins encoded by the Bcl-2 family.

Small molecule drugs, like CHML, are able to specifically modulate the activity of the caspase family, the Bcl-2 family, or other key points in the apoptotic pathway, and exert control over the cell death process and have utility in diseases characterized by either excessive or insufficient levels of apoptosis.

The caspases are a family of proteases responsible for carrying out the cell death process. In a living cell, these proteases are kept inactive by proteins on the mitochondrial cell surface from the BcL-2 family. When a cell is exposed to cell death signals such as ischemia, chemotherapy or radiation, BcL-2 function is blocked and caspase activators initiate the cell death cascade.

CHML is able to specifically modulate key points in the apoptotic pathway.

Specific Mechanism:
p53 protein, commonly referred to as "the tumor suppressor gene," is a key player in the cellular apoptosis process. Bio-therapeutic activation of this pathway has been a popular target for recent drug discovery technology.

p53, Bax and p21 protein levels were measured by immunoblotting assay, in MCF-7, ML-1, H1299 (human lung carcinoma) and RKO (human colon cancer,) cell lines after treatment with CHML. p53 protein was found to be elevated in the MCF-7, RKO and ML-1 cells.

As the ability to induce apoptosis is not limited to p53 positive cell lines, it appears that CHML is able to provoke apoptosis through both p53-dependant and -independent pathways.

Core Technologies:
Supporting GLORY's drug discovery program, is a sophisticated new technology for drug administration. Arterial Infusion using DSA is a fast developing science, administered by trained Interventional Radiologists. Formerly used in the management of Cardiology related conditions, the technology is capable of delivering concentrated drugs to a highly specific site (e.g. tumor,) via the arterial network.
Diagnostics:
DSA is capable of delivering concurrent imaging of the intricate vasculature of the tumoral network. This is used to guide the delivery of CHML, as well as measure the immediate effects on the tumor's blood supply network.

In recent studies, CHML was able to effect significant disruptions to the tumoral vasculature network in a number of various malignancies. In virtually every case, marked destruction of the tumor's feeding system could be observed in less than 30 minutes.

These data provide further corroboration of CHML's ability to penetrate a number of difficult tumors."

The CHML treatment is available in an offshore clinic.
The present cost of the full treatment, that lasts one to three months, is approx. $25,000.

For Information contact:
Sean A. Cohen,
11500 Silvergate Dr.
Dublin, CA 94568-2707

Phone: (925) 828-5093

Send mail to:
International Business Offices
Glory Pharmaceuticals
4020 Washington Blvd, Suite 309
Arlington, VA 22201

Phone: (703) 204-2657
Fax: (703) 204-2658

TOP